Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11

The Lancet Respiratory Medicine

Volumn 2, Issue 7, 2014, Pages 566-572

  Raghu, Ganesh ^a   Chen, Shih Yin ^b   Yeh, Wei Shi ^b   Maroni, Brad ^b   Li, Qian ^c   Lee, Yuan Chi ^c   Collard, Harold R ^d  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b BIOGEN   (United States)

^c EVIDERA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALGORITHM; ARTICLE; BIOSTATISTICS; COHORT ANALYSIS; EPIDEMIOLOGICAL DATA; FEMALE; FIBROSING ALVEOLITIS; HUMAN; ICD-9; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; SURVIVAL TIME; UNITED STATES; VERY ELDERLY; AGE; IDIOPATHIC PULMONARY FIBROSIS; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; MALE; MEDICARE; PREVALENCE; SEX FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84904006129     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70101-8     Document Type: Article

References (27)

1. Michaelson JE, Aguayo SM, Roman J Idiopathic pulmonary fibrosis: a practical approach for diagnosis and management. Chest 2000, 118:788-794.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
3. Meltzer EB, Noble PW Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008, 3:8.
4. King TE, Pardo A, Selman M Idiopathic pulmonary fibrosis. Lancet 2011, 378:1949-1961.
5. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005, 142:963-967.
6. Ley B, Collard HR, King TE Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431-440.
7. King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001, 164:1171-1181.
8. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531-537.
9. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
10. Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010, 137:129-137.
11. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012, 21:355-361.
12. Coultas DB, Zumwalt RE, Black WC, Sobonya RE The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994, 150:967-972.
13. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:810-816.
14. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000, 161:646-664. American Thoracic Society, European Respiratory SocietyEuropean Respiratory Society.
15. Mannino DM, Etzel RA, Parrish RG Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data. Am J Respir Crit Care Med 1996, 153:1548-1552.
16. Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllarniemi M Idiopathic pulmonary fibrosis-a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med 2013, 13:53.
17. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002, 165:277-304. American Thoracic Society, European Respiratory SocietyEuropean Respiratory Society.
18. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011, 66:462-467.
19. Ohno S, Nakaya T, Bando M, Sugiyama Y Idiopathic pulmonary fibrosis-results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 2008, 13:926-928.
20. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012, 156:684-691.
21. Atkins CP, Loke YK, Wilson AM Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials. Respir Med 2014, 108:376-387.
22. Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994, 149:450-454.
23. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998, 157:1063-1072.
24. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157:199-203.
25. Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM, Coultas DB Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998, 53:469-476.
26. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977. Idiopathic Pulmonary Fibrosis Clinical Research Network.
27. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007, 176:277-284.